Moderate and severe neutropenia in patients with systemic lupus erythematosus

Rheumatology

Volumn 45, Issue 8, 2006, Pages 994-998

  Martinez Banos D ^a   Crispin J C ^a   Lazo Langner, A ^a   Sanchez Guerrero J ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Granulocytopenia; Neutropenia; Systemic lupus erythematosus

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMOXICILLIN PLUS CLAVULANIC ACID; AZATHIOPRINE; CISAPRIDE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; LIVER ENZYME; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENYTOIN; PREDNISOLONE;

ADULT; BONE MARROW HYPOPLASIA; BONE MARROW TOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DYSERYTHROPOIESIS; EOSINOPHILIA; FEMALE; GRANULOCYTE; GRANULOCYTOPENIA; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; BONE MARROW; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; NEUTROPENIA; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 33747835638     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel016     Document Type: Review

References (19)

1. Rosenthal N, Farhi D. Bone marrow findings in connective tissue disease. Am J Clin Pathol 1989;92:650-4.
2. Bacon BR, Truehaft WH, Goodman AM. Azathioprine-induced pancytopenia. Occurrence in two patients with connective-tissue disease. Arch Intern Med 1981;141:223-6.
3. Heartman K. Anti-neutrophil antibodies of the immunoglobulin M class in autoimmune neutropenia. Am J Med Sci 1994;308:102-5.
4. Jonsson H, Sturfelt G. A novel assay for neutrophil clustering activity of human sera: Relation to disease activity and neutropenia in systemic lupus erythematosus. Ann Rheum Dis 1990;49:46-50.
5. Abramson SB, Given WP, Edelson HS, Weissmann G. Neutrophil aggregation induced by sera from patients with active systemic lupus erythematosus. Arthritis Rheum 1983;26:630-6.
6. Anderson RL, Bagby GC Jr, Richert-Boe K, Magenis RE, Koler RD. Therapy-related preleukemic syndrome. Cancer 1981; 47:1867-71.
7. Reveille JD, Bartolucci A, Alarcon GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990;33:37-48.
8. Hellmich B, Csernok E, de Hass M et al. Low Fc-gamma receptor III and high granulocyte colony-stimulating factor serum levels correlate with the risk of infection in neutropenia due to Felty's syndrome or systemic lupus erythematosus. Am J Med 2002;113:134-9.
9. Breedveld FC, Fibbe WE, Hermans J, van der Meer JW, Cats A. Factors influencing the incidence of infections in Felty's syndrome. Arch Intern Med 1987;147:915-20.
10. Campion G, Maddison PJ, Goulding N et al. The Felty syndrome: A case-matched study of clinical manifestations and outcome, serologic features and immunogenetic associations. Medicine 1990;79:69-80.
11. Quismorio FP Jr. Hematologic and lymphoid abnormalities in systemic lupus erythematosus. In: Wallace DJ, Hahn BH, eds. Dubois' lupus erythematosus. Philadelphia, PA: Lippincott Williams & Wilkins, 2002:793-819.
12. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
13. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
14. Guzmán J, Cardiel MH, Arce-Salinas A, Sánchez-Guerrero J, Alarcón-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992;19:1551-8.
15. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the systemic lupus international collaborating clinics/ American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
16. Michael SR. The hematologic aspects of disseminated lupus erythematosus. Blood 1951;6:1059-72.
17. Alarcón-Segovia D, López-Amor E, Cordova MS. Lupus eritematoso generalizado con agranulocitosis y anemia hemolítica por drogas. Prensa Med Mex 1968;7:245.
18. Deleze M, Alarcón-Segovia D, Oria CV et al. Hemocytopenia in systemic lupus erythematosus. Relationship to antiphospholipid antibodies. J Rheumatol 1989;16:926-30.
19. MacDuffie FC. Bone marrow depression after drug therapy in patients with systemic lupus erythematosus. Ann Rheum Dis 1965;24:289-92.